A Phase 2, Randomized, Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor Agonist in Obese Subjects with Prader-Willi Syndrome on Safety, Weight Reduction, and Food-Related Behaviors